Pulmonx reports Q1 EPS (33c), consensus (33c)

Reports Q1 revenue $20.59M, consensus $20.43M. “During the first quarter we initiated our refreshed U.S. commercial strategies and continued to execute in our direct international markets. We are encouraged by early signs of progress from the actions we have taken to refocus our U.S. sales organization and advance our clinical programs,” said Glen French, President and Chief Executive Officer of Pulmonx (LUNG). “With a fully staffed global sales organization, we remain confident in our ability to drive sequential improvement in revenue growth, execute against our strategic priorities, and deliver meaningful operating leverage in 2026.”